Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERGO Entia Biosciences		$0.00	$0.00 ▼ $0.00	N/A	N/A	N/A	N/A
GRI GRI Bio	$1.32 +3.1%	$1.54	$1.10 ▼ $30.43	$3.30M	-1.61	279,703 shs	279,984 shs
SLN Silence Therapeutics	$6.17 +0.2%	$5.81	$1.97 ▼ $20.48	N/A	1.39	85,454 shs	62,280 shs
SLS SELLAS Life Sciences Group	$1.66 +4.4%	$1.80	$0.77 ▼ $2.27	$165.63M	2.26	2.69 million shs	1.83 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERGO Entia Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
GRI GRI Bio	0.00%	-33.67%	-8.33%	-37.14%	-89.86%
SLN Silence Therapeutics	0.00%	-2.68%	+11.37%	+57.00%	-69.90%
SLS SELLAS Life Sciences Group	0.00%	-7.78%	-23.68%	-4.60%	+43.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ERGO Entia Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GRI GRI Bio	1.9994 of 5 stars	3.5	2.0	0.0	0.0	1.5	0.0	1.3
SLN Silence Therapeutics	1.8618 of 5 stars	3.4	3.0	0.0	0.0	0.0	1.7	0.6
SLS SELLAS Life Sciences Group	2.3323 of 5 stars	3.5	1.0	0.0	0.0	3.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERGO Entia Biosciences	0.00	N/A	N/A	N/A
GRI GRI Bio	3.00	Buy	$22.00	1,566.67% Upside
SLN Silence Therapeutics	2.71	Moderate Buy	$33.83	448.35% Upside
SLS SELLAS Life Sciences Group	3.00	Buy	$7.00	321.69% Upside

Current Analyst Ratings Breakdown

Latest SLN, GRI, SLS, and ERGO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	SLS SELLAS Life Sciences Group	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $7.00
6/13/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
6/13/2025	SLN Silence Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
6/11/2025	GRI GRI Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/27/2025	GRI GRI Bio	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $34.00
5/9/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$4.00 ➝ $3.00
5/9/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $25.00
5/9/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $35.00

(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERGO Entia Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
GRI GRI Bio	N/A	N/A	N/A	N/A	$7.68 per share	N/A
SLN Silence Therapeutics	$43.26M	N/A	N/A	N/A	$4.48 per share	N/A
SLS SELLAS Life Sciences Group	$1M	165.63	N/A	N/A	$0.13 per share	12.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERGO Entia Biosciences	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
GRI GRI Bio	-$8.21M	-$11.56	N/A	N/A	N/A	N/A	-275.15%	-168.22%	8/12/2025 (Estimated)
SLN Silence Therapeutics	-$45.31M	-$1.50	N/A	N/A	N/A	-260.55%	-56.17%	-33.96%	8/21/2025 (Estimated)
SLS SELLAS Life Sciences Group	-$30.88M	-$0.38	N/A	N/A	N/A	N/A	-193.67%	-113.02%	8/12/2025 (Estimated)

Latest SLN, GRI, SLS, and ERGO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	SLN Silence Therapeutics	-$0.2067	N/A	N/A	N/A	$3.38 million	N/A
8/12/2025	Q2 2025	GRI GRI Bio	-$1.31	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	SLS SELLAS Life Sciences Group	-$0.0767	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	GRI GRI Bio	-$4.08	-$5.80	-$1.72	-$5.80	N/A	N/A
5/13/2025	Q1 2025	SLS SELLAS Life Sciences Group	-$0.1067	-$0.07	+$0.0367	-$0.07	N/A	N/A
5/8/2025	Q1 2025	SLN Silence Therapeutics	-$0.18	-$0.60	-$0.42	-$0.60	$3.58 million	$0.14 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERGO Entia Biosciences	N/A	N/A	N/A	N/A	N/A
GRI GRI Bio	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERGO Entia Biosciences	N/A	N/A	N/A
GRI GRI Bio	N/A	1.41	1.41
SLN Silence Therapeutics	N/A	8.81	8.81
SLS SELLAS Life Sciences Group	N/A	4.64	4.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERGO Entia Biosciences	N/A
GRI GRI Bio	33.95%
SLN Silence Therapeutics	98.73%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
ERGO Entia Biosciences	28.30%
GRI GRI Bio	0.13%
SLN Silence Therapeutics	4.10%
SLS SELLAS Life Sciences Group	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERGO Entia Biosciences	6	N/A	N/A	Not Optionable
GRI GRI Bio	1	2.50 million	2.49 million	Not Optionable
SLN Silence Therapeutics	100	N/A	N/A	Not Optionable
SLS SELLAS Life Sciences Group	10	99.78 million	98.38 million	Not Optionable

SLN, GRI, SLS, and ERGO Headlines

Recent News About These Companies

SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)

July 31 at 8:06 PM | zacks.com

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 1.8% - What's Next?

July 31 at 3:36 AM | marketbeat.com

SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

July 30, 2025 | marketbeat.com

SELLAS Life Sciences Group (NASDAQ:SLS) Price Target Raised to $7.00

July 16, 2025 | marketbeat.com

Sellas Flat on Trial Success

July 16, 2025 | baystreet.ca

SELLAS gains as mid-stage trial for leukemia drug succeeds

July 16, 2025 | msn.com

SELLAS Life Sciences Group Welcomes Dr. Linghua Wang to Scientific Advisory Board - Nasdaq

July 9, 2025 | nasdaq.com

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 3.7% - Here's What Happened

July 9, 2025 | marketbeat.com

Sellas Life Sciences appoints Linghua Wang to Scientific Advisory Board

July 7, 2025 | msn.com

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

July 7, 2025 | globenewswire.com

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?

June 23, 2025 | zacks.com

Sellas Life Sciences: Tons Of Completed Studies

June 17, 2025 | seekingalpha.com

Nostrand Robert L. Van Purchases 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Stock

June 14, 2025 | insidertrades.com

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

June 5, 2025 | globenewswire.com

SELLAS Life Sciences Presents Preclinical Data on SLS009 as a Targeted Therapy for ASXL1 Mutated Colorectal Cancer at ASCO 2025

June 4, 2025 | nasdaq.com

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Jane Wasman Buys 20,000 Shares

June 3, 2025 | insidertrades.com

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

June 2, 2025 | globenewswire.com

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 20, 2025 | globenewswire.com

SELLAS Life Sciences Group, Inc. Common Stock

May 16, 2025 | fxempire.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
How a Government Loan Changes the Game for Plug Power
By Jeffrey Neal Johnson | July 4, 2025
View How a Government Loan Changes the Game for Plug Power
America Wants Drone Dominance: Are These Stocks Ready to Soar?
By Chris Markoch | July 20, 2025
View America Wants Drone Dominance: Are These Stocks Ready to Soar?
A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3
By Thomas Hughes | July 24, 2025
View A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3

SLN, GRI, SLS, and ERGO Company Descriptions

Entia Biosciences OTCMKTS:ERGO

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.

GRI Bio NASDAQ:GRI

$1.32 +0.04 (+3.13%)

As of 08/1/2025 04:00 PM Eastern

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Silence Therapeutics NASDAQ:SLN

$6.17 +0.01 (+0.16%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$6.15 -0.02 (-0.32%)

As of 08/1/2025 07:47 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

SELLAS Life Sciences Group NASDAQ:SLS

$1.66 +0.07 (+4.40%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.65 -0.01 (-0.60%)

As of 08/1/2025 07:59 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time